(Health Korea News / Do-i Lim) Boryung (formerly Boryung Pharmaceutical) continued its high growth in the first half of this year with the promotion of its main products, achieving its best performance for the first half of the year.
Boryeong announced on the 31st through a provisional performance announcement that it recorded sales of 489.2 billion won and operating profit of 36.5 billion won in the first half of 2024 (on a consolidated basis). These figures represent a 16% and 4% increase, respectively, compared to the same period last year.
While all of Boryeong’s specialty pharmaceutical divisions grew evenly, the new hypertension drug ‘Kanab’ product line in particular showed a high sales growth rate of 13%, reaching the 70 billion won mark in half-year sales for the first time.
The Onco (anticancer drug) division, which exceeded KRW 100 billion in sales in the first half of last year for the first time, also grew by more than 8% year-on-year, and sales of the anticancer drug Gemza also increased by 23% in the first half, expanding prescriptions for all LBA (Legacy Brands Acquisition, original brand acquisition) items.
The diabetes and dyslipidemia products that Borum is focusing on at the company level have also successfully settled into the initial market and established themselves as growth products. In particular, the diabetes treatment drug ‘Trudapa’ has been ranked first in the generic dapagliflozin market since its launch in April of last year.
Boryeong plans to continue its growth in the second half of the year with chronic disease treatment drugs and anticancer drugs as its two mainstays. It plans to build a foundation for sustainable growth by strengthening profitability through the conversion of its LBA product, schizophrenia treatment ‘Zyprexa’, to its own production and the development of various in-house products.
Boryeong CEO Jang Du-hyeon said, “This year, despite the unstable economic situation due to exchange rates and prices, as well as the difficult business environment, we are one step closer to our goal of ‘leaping forward to become a leading pharmaceutical company’ by maintaining high sales growth, which is meaningful,” and added, “We will focus our capabilities on strengthening the competitiveness of our pharmaceutical business based on fostering our own products and continuous innovation.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
